Back by Popular Demand - KRAS G12C Mutation: An Emerging Biomarker for NSCLC Sponsored by Amgen®

IE users – if you are experiencing issues trying to register for this webinar, please use Chrome, Safari or Firefox.

Tuesday, May 4, 2021
12:00 PM ET/9:00 AM PT

Program objectives:
At the conclusion of this program, participants will be able to:
• The evolution of biomarkers in NSCLC
• KRAS and KRASG12C prevalence information
• Diagnostic strategies and options for KRASG12C testing
 
Dr Fesko and Dr Hooper will review the science behind the KRASG12C emerging biomarker.
 
Yuri Fesko, MD
Chief Clinical Officer, Oncology Quest Diagnostics
Secaucus, New Jersey
 
 
Kari Hooper, MD
Pathologist, AmeriPath®/Quest Diagnostics; Department Chair, 
Integris Baptist Medical Center Oklahoma City, Oklahoma